Nyxoah

About

Funding history · 9 rounds · $301.2M total

Headcount over time

Offices

Q&A

What is Nyxoah's primary focus?

Nyxoah is a medical technology company focused on developing and commercializing innovative solutions to treat Obstructive Sleep Apnea (OSA).

When did Nyxoah go public on Euronext and NASDAQ?

Nyxoah went public on Euronext in September 2020 and on NASDAQ in July 2021.

What was the amount raised in Nyxoah's C Round funding in February 2020?

In February 2020, Nyxoah raised $27,000,000 in a C Round funding, with lead investors including ResMed Inc.

What was the amount raised in Nyxoah's Public Offering in May 2024?

In May 2024, Nyxoah raised $49,716,483.75 through a Public Offering.

What was the amount raised in Nyxoah's most recent Public Offering?

In June 2026, Nyxoah raised $94,999,999.76 in a Public Offering.

What is the current employee count for Nyxoah?

Nyxoah currently has 154 employees, falling within the 51-200 employee bucket.

What was a significant regulatory milestone achieved by Nyxoah in March 2023?

In March 2023, Nyxoah announced the achievement of key clinical and regulatory milestones, including raising $3 million from an At-the-Market Equity Offering.

What was a key partnership announced by Nyxoah in September 2023?

In September 2023, Nyxoah announced a partnership with ResMed in Germany.

What was a significant product development for Nyxoah in July 2022?

In July 2022, Nyxoah announced CE Mark Approval for its Genio® 2.1 system.

What was a major FDA-related update for Nyxoah in August 2025?

In August 2025, Nyxoah received approval from the FDA for its Genio® System for the treatment of Obstructive Sleep Apnea.

Team · 13

Robert Taub

Founder · Co-founder & Chairman

Olivier Taelman

CEO & Executive Director

John Landry

Chief Financial Officer

Scott Holstine

Chief Commercial Officer

Bruno Onkelinx

Chief Technology Officer

Dr. Maurits S. Boon

Chief Medical Officer

Jey Subbaroyan

Chief Science Officer

Geeta Kaveti

Chief Compliance Officer

An Moonen

General Counsel

Loïc Moreau

President International

Kevin Rakin

Independent Non-Executive Director

Jürgen Hambrecht

Director

Daniel Wildman

Independent Director

Sectors & technology

Highlights

Tags